These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 7018668)

  • 21. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice.
    Kennel SJ; Lankford PK; Flynn KM; Winegar R
    Cancer Res; 1985 Aug; 45(8):3782-9. PubMed ID: 2410101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation.
    Weiss L; Morecki S; Vitetta ES; Slavin S
    J Immunol; 1983 May; 130(5):2452-5. PubMed ID: 6339628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined effects of immunity and antitumor drugs against cancer. I. In vivo studies with cis-diamminedichloroplatinum and cyclophosphamide in mouse models.
    Ricci F; De Filippi R; Riccardi C; Romani L; Giuliani A
    Chemioterapia; 1987 Dec; 6(6):403-9. PubMed ID: 3435922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice.
    Chester SJ; Esparza AR; Flinton LJ; Simon JD; Kelley RJ; Albala MM
    Cancer Res; 1977 Oct; 37(10):3494-6. PubMed ID: 20223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
    Greenberg PD; Cheever MA
    J Immunol; 1984 Dec; 133(6):3401-7. PubMed ID: 6149246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
    Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
    Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Moloney murine lymphoma and sarcoma growth in vivo by dietary retinoids.
    Dillehay DL; Shealy YF; Lamon EW
    Cancer Res; 1989 Jan; 49(1):44-50. PubMed ID: 2783245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
    Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
    J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
    Laude M; Siessmann KL; Mokyr MB; Dray S
    Cancer Res; 1991 Sep; 51(17):4516-22. PubMed ID: 1873795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.
    Bernstein ID
    J Immunol; 1977 Jan; 118(1):122-8. PubMed ID: 830744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic cell therapy for a murine mammary carcinoma.
    Morecki S; Yacovlev E; Diab A; Slavin S
    Cancer Res; 1998 Sep; 58(17):3891-5. PubMed ID: 9731499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anergic cells induced by the blockade of CD40-CD154 and CD28-B7 costimulatory pathways act as potent immunoregulatory cells in vitro and vivo.
    Cai Y; Zhou PJ; Tang XD
    Chin Med J (Engl); 2004 Aug; 117(8):1178-83. PubMed ID: 15361291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
    Nitta K; Tanaka T; Takeuchi M
    Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
    Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.